Palvella Therapeutics, Inc.
PVLA•NASDAQ•Healthcare•Biotechnology

About Palvella Therapeutics

Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. The company's lead product candidate is QTORIN 3.9% rapamycin anhydrous gel that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations. It also develops QTORIN rapamycin for the treatment of other mTOR-driven skin diseases. The company is based in Wayne, Pennsylvania

Company Information

SectorHealthcare
IndustryBiotechnology
CEOWesley Kaupinen
Founded2015
Employees14
CountryUnited States
Fiscal YearJanuary - December

Stock Details

ExchangeNASDAQ (NASDAQ)
CurrencyUSD - USD
TypeStock
SubtypeCommon Stock

Contact Information

Websitepalvellatx.com
Phone484 253 1461
Address
125 Strafford Avenue, Suite 360 Wayne, Pennsylvania 19087 United States

Corporate Identifiers

CIK0001742961
CUSIP697947109
ISINUS6979471090
EIN81-2228053
SIC2834

Leadership Team & Key Executives

Wesley H. Kaupinen
Founder, President, Chief Executive Officer and Director
Kathleen Goin
Chief Operating Officer
Dr. Jeffrey Martini Ph.D.
Chief Scientific Officer
Matthew E. Korenberg
Chief Financial Officer and Treasurer
Bohan Wei
Vice President of Corporate Development and New Product Planning
Emily Cook
Senior Vice President of Clinical Operations
Jason Burdette
SVice President of CMC and Technical Operations
Ashley Kline
Chief Commercial Officer
Dr. David W. Osborne Ph.D.
Chief Innovation Officer